Compare UTZ & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UTZ | GYRE |
|---|---|---|
| Founded | 2018 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 681.8M | 679.4M |
| IPO Year | 2018 | 2004 |
| Metric | UTZ | GYRE |
|---|---|---|
| Price | $7.36 | $7.31 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 2 |
| Target Price | $11.93 | ★ $17.00 |
| AVG Volume (30 Days) | ★ 1.7M | 52.0K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | ★ 3.32% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,438,800,000.00 | $275,000.00 |
| Revenue This Year | $5.16 | $19.88 |
| Revenue Next Year | $1.45 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2.09 | N/A |
| 52 Week Low | $7.12 | $6.58 |
| 52 Week High | $14.67 | $11.67 |
| Indicator | UTZ | GYRE |
|---|---|---|
| Relative Strength Index (RSI) | 42.67 | 46.37 |
| Support Level | $7.27 | $6.90 |
| Resistance Level | $8.01 | $8.28 |
| Average True Range (ATR) | 0.35 | 0.37 |
| MACD | -0.03 | -0.06 |
| Stochastic Oscillator | 10.47 | 26.76 |
Utz Brands Inc is a manufacturer of branded salty snacks based in the United States. It produces various salty snack foods, including potato chips, tortilla chips, pretzels, cheese snacks, party mixes, pork skins, ready-to-eat popcorn, and other snacks, which include salsa and dips. These products are offered through its flagship brands like Utz, On The Border, Zapp's, and Boulder Canyon, along with other brands, including Golden Flake, Miguelito's, Hawaiian, Bachman, Tim's Cascade, Dirty Potato Chips, TGI Fridays, and Vitner's. The company's products are packaged in a variety of different sizes and configurations, ranging from individual packages to shareable bulk containers. It also sells certain third-party branded products through its distribution network.
Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.